Opinions of parents about school-entry mandates for the human papillomavirus vaccine

Journal of Lower Genital Tract Disease

Volumn 14, Issue 1, 2010, Pages 43-48

  Horn, Leslie ^a   Howard, Casey ^a   Waller, Jennifer ^b   Ferris, Daron G ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Gynecologic Cancer Prevention Center   (United States)

Author keywords

Human papillomavirus; Mandatory vaccines; Questionnaire; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; DRUG SAFETY; FEMALE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN RIGHTS; MALE; MANDATORY PROGRAM; PARENTAL ATTITUDE; SCHOOL HEALTH SERVICE; VACCINATION; WART VIRUS;

ADOLESCENT; CHILD; FEMALE; HUMANS; MALE; MANDATORY PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PARENTS; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; SCHOOLS; VACCINATION;

EID: 76149136018     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e3181b0fad4     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention. Division of STD Prevention, National Center for HIV, STD, and TB Prevention Program Brochure. Human Papillomavirus: HPV Information for Clinicians. Atlanta, GA: Centers for Disease Control and Prevention, 2007.
2. Koutsky L. Epidemiology of genital human papillomavirus infection. Am Med 1997;102:3-8. (Pubitemid 127695953)
3. A human papillomavirus vaccine. Med Lett Drugs Ther 2006;48:65-6.
4. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virusYlike particle vaccine in young women: a randomized double-blind placebocontrolled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
5. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
6. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virusYlikeYparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ. A combined analysis of four randomized clinical trials. Lancet 2007;369:1861-8.
7. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43. (Pubitemid 46740303)
8. Advisory Committee on Immunization Practices (ACIP). Vaccines for children programVVaccine to prevent human papillomavirus (HPV) infection. Available at: www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/ 0606hpv.pdf. Accessed on May 2008.
9. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Lower Gen Tract Dis 2004;8:188-94.
10. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med 2004;58:1405-13.
11. ZimetGD, Mays RM, Sturm LA,Ravert AA, Perkins SM, Juliar BE. Parental attitudes about sexually transmitted infection vaccination for their adolescent children. Arch Pediatr Adolesc Med 2005;159:132-7.
12. Averhoff F, Linton L, Peddecord KM, Edwards C, Wang W, Fishbein D. A middle school immunization law rapidly and substantially increases immunization coverage among adolescents. Am J Public Health 2004;94:978-84.
13. Fogarty KJ, Massoudi MS, Gallo W, Averhoff FM, Yusuf H, Fishbein D. Vaccine coverage levels after implementation of a middle school vaccination requirement, Florida, 1997-2000. Public Health Rep 2004;119:163-9.
14. Olshen E, Mahon BE, Wang S, Woods ER. The impact of state policies on vaccine coverage by age 13 in an insured population. J Adolesc Health 2007;40:405-11.
15. Morita JY, Ramirez E, Trick WE. Effect of a schoolentry vaccination requirement on racial and ethnic disparities in hepatitis B immunization coverage levels among public school students. Pediatrics 2008;121:547-52.
16. Wilson TR, Fishbein DB, Ellis PA, Edlavitch SA. The impact of a school entry law on adolescent immunization rates. J Adolesc Health 2005;37:511-6.
17. Ferris DG, Waller JC, Owen A, Smith. Mid-adult women's attitudes about receiving the prophylactic human papillomavirus vaccine. J Low Genit Tract Dis 2007;11: 166-72.
18. Ferris DG, Waller JL, Miller J, Patel P, Jackson L, Price GA, et al. Men's attitudes toward receiving the human papillomavirus vaccine. J Low Genit Tract Dis 2008;12:276-81.
19. Rosenthal E. Researchers question wide use of HPV vaccines. New York Times. August 21, 2008.
20. Gostin LO, DeAngelio CD. Mandatory HPV vaccination, public health vs private wealth. JAMA 2007;297:1921-3.